Olanzapine versus typical neuroleptics for schizophrenia: evaluation of social and economic costs. Farmeconomia. Health Economics and Therapeutic Pathways, [S. l.], v. 7, n. 2, p. 119–124, 2006. DOI: 10.7175/fe.v7i2.681. Disponível em: https://journals.seedstm.com/index.php/FE/article/view/681. Acesso em: 29 dec. 2025.